Cellectis (NASDAQ:CLLS) Stock Crosses Above Fifty Day Moving Average – Should You Sell?

Shares of Cellectis S.A. (NASDAQ:CLLS) passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $4.17 and traded as high as $4.46. Cellectis shares last traded at $4.37, with a volume of 406,309 shares changing hands.

Analyst Ratings Changes

CLLS has been the subject of several recent research reports. Wall Street Zen upgraded shares of Cellectis to a “hold” rating in a research report on Saturday, September 20th. Wells Fargo & Company reiterated a “positive” rating and issued a $4.00 price objective on shares of Cellectis in a report on Monday, October 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a report on Wednesday, October 8th. Finally, Barclays boosted their target price on Cellectis from $4.00 to $8.00 and gave the stock an “overweight” rating in a research report on Friday, October 17th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $6.00.

Cellectis Stock Performance

The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.49 and a current ratio of 1.49. The company has a fifty day simple moving average of $4.17 and a two-hundred day simple moving average of $3.04.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings results on Friday, November 7th. The biotechnology company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.11. Cellectis had a negative return on equity of 51.22% and a negative net margin of 58.06%.The company had revenue of $37.16 million for the quarter, compared to analyst estimates of $8.22 million. Analysts predict that Cellectis S.A. will post -0.46 earnings per share for the current year.

Institutional Investors Weigh In On Cellectis

Several large investors have recently made changes to their positions in the stock. OLD Mission Capital LLC bought a new stake in Cellectis in the 1st quarter valued at $31,000. Acadian Asset Management LLC lifted its holdings in shares of Cellectis by 132.9% in the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 26,461 shares in the last quarter. Delaney Dennis R acquired a new position in shares of Cellectis during the third quarter worth about $68,000. Virtu Financial LLC bought a new position in shares of Cellectis during the third quarter worth about $72,000. Finally, Millennium Management LLC grew its holdings in shares of Cellectis by 61.9% during the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock worth $165,000 after buying an additional 22,080 shares in the last quarter. Institutional investors own 63.90% of the company’s stock.

About Cellectis

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.